Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liesbeth Everix

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and TherapyLiesbeth Everix, Elsie Neo Seane, Thomas Ebenhan, et al.
Neuroimage. Clinical|May 17, 2025
Assessment of changes in synaptic density in the zQ175DN mouse model of Huntington's disease: a [<sup>18</sup>F]SynVesT-1 studyLiesbeth Everix, Franziska Zajicek, Annemie Van Eetveldt, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|April 20, 2026
Comparing kinetic profiles of SV2A radiotracers [<sup>18</sup>F]SynVesT-1 and [<sup>18</sup>F]UCB-J using PET imaging in miceLiesbeth Everix, Alan Miranda, Jordy Akkermans, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 4, 2024
Preclinical validation and kinetic modelling of the SV2A PET ligand [<sup>18</sup>F]UCB-J in miceLiesbeth Everix, Filipe Elvas, Alan Miranda Menchaca, et al.
Cancers|April 12, 2022
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of GlioblastomaLiesbeth Everix, Shankari Nair, Cathryn H S Driver, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 18, 2025
Preclinical evaluation of [<sup>11</sup>C]CHDI-009R for quantification of mutant huntingtin aggregatesFranziska Zajicek, Liesbeth Everix, Annemie Van Eetveldt, et al.
Neurobiology of Disease|April 9, 2025
Pharmacodynamic biomarkers responsive to mutant huntingtin lowering in a Huntington's disease mouse modelDeanna M Marchionini, Stef De Lombaerde, Joëlle van Rijswijk, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and TherapyLiesbeth Everix, Elsie Neo Seane, Thomas Ebenhan, et al.
Neuroimage. Clinical|May 17, 2025
Assessment of changes in synaptic density in the zQ175DN mouse model of Huntington's disease: a [<sup>18</sup>F]SynVesT-1 studyLiesbeth Everix, Franziska Zajicek, Annemie Van Eetveldt, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|April 20, 2026
Comparing kinetic profiles of SV2A radiotracers [<sup>18</sup>F]SynVesT-1 and [<sup>18</sup>F]UCB-J using PET imaging in miceLiesbeth Everix, Alan Miranda, Jordy Akkermans, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 4, 2024
Preclinical validation and kinetic modelling of the SV2A PET ligand [<sup>18</sup>F]UCB-J in miceLiesbeth Everix, Filipe Elvas, Alan Miranda Menchaca, et al.
Cancers|April 12, 2022
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of GlioblastomaLiesbeth Everix, Shankari Nair, Cathryn H S Driver, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 18, 2025
Preclinical evaluation of [<sup>11</sup>C]CHDI-009R for quantification of mutant huntingtin aggregatesFranziska Zajicek, Liesbeth Everix, Annemie Van Eetveldt, et al.
Neurobiology of Disease|April 9, 2025
Pharmacodynamic biomarkers responsive to mutant huntingtin lowering in a Huntington's disease mouse modelDeanna M Marchionini, Stef De Lombaerde, Joëlle van Rijswijk, et al.
Pageof 1